More Blood Pressure Medication Recalled Over Carcinogen Concerns

Another drug company has recalled a version of losartan blood pressure medication over concerns the drug contains tiny amounts of a carcinogen.

Torrent Pharmaceuticals last week recalled eight more lots of losartan potassium tablets, on top of the two it recalled last month.

In a notice shared by the Food and Drug Administration, the India-based pharmaceutical company said the medication used to treat high blood pressure and diabetic kidney disease contained unacceptable levels of the human carcinogen N-nitrosodiethylamine.

The drugs contained an active ingredient made by Hetero Labs in India, one of two overseas factories linked to more than a dozen recalls of commonly prescribed blood pressure drugs since July.

The recalled drugs include versions of valsartan, losartan and irbesartan, either alone or in combination with other drugs. Consumers can view a complete list of FDA updates on the recalls, including affected dosages and drug combinations, on the agency’s website.

The recalled drugs are part a large class of drugs called angiotensin II receptor blockers, which work by blocking the effects of a hormone that narrows blood vessels.

ARBs and another class of drugs called angiotensin converting-enzyme inhibitors, or ACE inhibitors, are often the first drugs doctors recommend to lower a patient’s blood pressure.

Physicians and researchers representing the American College of Cardiology, the American Heart Association and nine other groups adopted new guidelines in 2017 that estimated 103 million U.S. adults had high blood pressure, up from 72 million based on an earlier standard.

Click here to read more.
Source: USA Today